)

Madrigal Pharmaceuticals (MDGL) investor relations material
Madrigal Pharmaceuticals Morgan Stanley 23rd Annual Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Key business developments
Achieved a strong quarter with $213 million in revenue and exceeded launch expectations for Rezdiffra.
Secured intellectual property protection for Rezdiffra through 2045, providing a long-term foundation.
Received European Commission approval and prepared for a launch in Germany, aiming for positive contribution in 2-3 years.
Entered a new licensing agreement for an oral GLP-1 asset and secured $500 million in financing to support growth.
Initiated commercial contracting with payers in Q2, with growth-to-net management evolving as planned.
Product performance and market insights
Rezdiffra launch metrics are among the best specialty launches in the last decade, with strong breadth of prescribing and over 23,000 patients on drug.
Real-world data shows Rezdiffra is well-tolerated and exceeds efficacy expectations, with notable improvements in liver stiffness and fibrosis reversal.
Patient adherence is high, with reauthorization at 12 months not posing issues; patients are motivated to stay on therapy.
Market penetration is at 7% of a 315,000-patient population, with significant growth potential as diagnosis and awareness increase.
About 50% of Rezdiffra patients have previously used GLP-1s, and 25% are on combination therapy.
Clinical and competitive landscape
Open-label data from the Maestro NAFLD study showed significant improvements in liver stiffness and biomarkers, supporting confidence in the ongoing Maestro Outcomes trial.
In the F4 cirrhosis population, 2/3 of high-risk patients improved their status after two years of therapy.
Rezdiffra is positioned as a first-mover in MASH, with competitors expected to drive further market expansion and awareness.
Payer discussions are ongoing, with step edits and pricing dynamics under evaluation as new competitors enter the market.
Next Madrigal Pharmaceuticals earnings date

Next Madrigal Pharmaceuticals earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage